Thanks to medical research and technology, people live longer than ever before. 35% of the population above the age of 70 suffer from mild cognitive impairment, and 40% of dementia cases are undiagnosed. We know the significance of today’s brain health challenges, and an aging population will only exasperate this in the future.
BrainSymph originates from the neurological environment at Oslo University Hospital and is a contributing partner in the EU-funded research project AI Mind. BrainSymph maps brain health and risk of developing dementia in a structured and efficient manner. Our innovative platform combines state-of-the-art methods with biomarkers and AI-driven technologies into one unique solution.
Currently, patient brain health isn’t examined until clear symptoms are present. At this point, brain disease has typically progressed too far for any effective preventative and therapeutic measures to be successful. Clinical brain health mapping is done at random and too late for productive intervention, and the process is time and resource intensive. Research has proven that early intervention can delay and impede cognitive decline.
The BrainSymph platform makes brain health mapping easy, systematic, and efficient at scale, so that healthcare professionals and patients can assess and understand brain health within an accessible, intuitive framework.
